SCHEMBL3499406

SCHEMBL3499406

COC(=O)C1=Cc2ccc(-c3ccc(Cl)cc3)cc2SC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.45
CA9 Q16790 5/20 0.45
CA2 P00918 1/20 0.45
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
SLC6A3 Q01959 8/20 0.40
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
ALDH1A1 P00352 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498102 0.84 ALAD (0.41) CA12NPC1RAB9A
SCHEMBL3498690 0.79 CA12 (0.39) CA12CA9CA2MAPTTP53
SCHEMBL7969353 0.69 SLC6A3 (0.40) CA12CA9CA2MAPTKDM4E
SCHEMBL24482978 0.67 CA12 (0.54) CA12CA9CA2SLC6A3SLC6A2
SCHEMBL5209272 0.67 ALDH1A1 (0.41) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL7931723 0.66 POLB (0.41) CA12CA9MAPTKDM4ERAB9A
SCHEMBL14926631 0.65 CA1 (0.58) CA12CA9CA2MAPTNPC1
SCHEMBL21585537 0.65 CA12 (0.63) CA12CA9CA2KDM4ESLC6A3
SCHEMBL7683946 0.65 KDM4E (0.43) CA12CA9CA2MAPTKDM4E
SCHEMBL11526406 0.65 CA12 (0.66) CA12CA9CA2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 CA12 2222/4885CA9 2862/4885CA2 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.